These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30488029)

  • 1. Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance.
    Niyazov A; Lenci D
    Front Public Health; 2018; 6():304. PubMed ID: 30488029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDAMA Section 114: Why the Renewed Interest?
    Perfetto EM; Burke L; Oehrlein EM; Gaballah M
    J Manag Care Spec Pharm; 2015 May; 21(5):368-74. PubMed ID: 25942998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 21st Century Cures Act: pharmacoeconomic boon or bane?
    Mendoza RL
    J Med Econ; 2017 Apr; 20(4):315-317. PubMed ID: 28092219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embracing 21st Century Information Sharing: Defining a New Paradigm for the Food and Drug Administration's Regulation of Biopharmaceutical Company Communications with Healthcare Professionals.
    Spears JM; Francer JK; Turner NA
    Food Drug Law J; 2015; 70(1):143-60, i-ii. PubMed ID: 26292475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act.
    Burris JF; Puglisi JT
    J Clin Pharmacol; 2018 Mar; 58(3):281-285. PubMed ID: 28981164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 21st century cures act: Opportunities and challenges.
    Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA modernization act of 1997: guidance on medical device tracking; availability--FDA. Notice.
    Fed Regist; 1998 Mar; 63(42):10640-1. PubMed ID: 10177505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best practices in designing preapproval information engagements for US health care decision makers.
    Dodda S; Bannister B; Hydery T; Gorey C; Dunlap S; Mody L
    J Manag Care Spec Pharm; 2023 Mar; 29(3):245-250. PubMed ID: 36840953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 21st Century Cures Act Implications for the Reduction of Racial Health Disparities in the US Criminal Justice System: a Public Health Approach.
    Cole DM; Thomas DM; Field K; Wool A; Lipiner T; Massenberg N; Guthrie BJ
    J Racial Ethn Health Disparities; 2018 Aug; 5(4):885-893. PubMed ID: 29124683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad.
    Selzman KA; Patel H; Cavanaugh K
    J Interv Card Electrophysiol; 2019 Nov; 56(2):173-182. PubMed ID: 31418099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
    Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
    Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 21st Century Cures Act on Patients and the Healthcare Team.
    Simmons V; Boman T; Stewart SA
    Clin J Oncol Nurs; 2024 Jan; 28(1):21-25. PubMed ID: 38252857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Evidence, Public Participation, and the FDA.
    Schwartz JL
    Hastings Cent Rep; 2017 Nov; 47(6):7-8. PubMed ID: 29171057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating Advances in Cancer Care Research: A Lookback at the 21st Century Cures Act in 2020.
    Gallo L; Walters RS; Allen J; Ahlstrom J; Alspach C; Biru Y; Schatz A; Martin K; Carlson RW
    J Natl Compr Canc Netw; 2021 Apr; 19(4):378-384. PubMed ID: 33845456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of FDA regulatory requirements for new medical devices.
    Sucher JF; Jones SL; Montoya ID
    Expert Opin Med Diagn; 2009 Jan; 3(1):5-11. PubMed ID: 23495960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Data Analytics Fit for Regulatory Decision-Making.
    Schneeweiss S; Glynn RJ
    Am J Law Med; 2018 May; 44(2-3):197-217. PubMed ID: 30106649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical devices; device tracking; new orders to manufacturers--FDA. Notice.
    Fed Regist; 1998 Mar; 63(42):10638-40. PubMed ID: 10177504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 21st Century Cures Act: can the regulatory framework survive the "cures"?
    Osorio-de-Castro CG; Caetano R; Pepe VL
    Cad Saude Publica; 2015 Sep; 31(9):1807-10. PubMed ID: 26578005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.